Oral Naltrexone in Hailey-Hailey Disease: Review of the Current Clinical Evidence.
Hailey-Hailey disease (HHD) is a rare, chronic dermatosis that has a significant negative impact on patients' quality of life due to recurrent painful erosions in intertriginous areas. Despite various available therapies, treatment remains challenging. Naltrexone, an opioid receptor antagonist, represents an emerging potential therapeutic option in refractory HHD. This review aimed to summarise the current evidence on efficacy and safety of naltrexone as a treatment for HHD, focusing on therapeutic outcomes, adverse effects, and clinical applicability in adult patients. A literature search was conducted for publications available up to December 2025. A total of 17 publications (11 case reports, 5 case series and 1 retrospective study) met the inclusion criteria, representing a total of 47 patients. Most patients had refractory HHD with poor response to conventional therapies. Treatment resulted in improvement - defined as clearance of lesions or reduction of affected body surface area (BSA), with no reported relapse - in 64% of patients (30 of 47). Thirty-eight patients received naltrexone monotherapy whilst 9 received other treatment concomitantly. Of the monotherapy patients 25 (65.8%) reported clinical improvement, compared with 5 of 9 (55.6%) receiving concomitant therapy. Using a more stringent definition of response (complete clearance or ≥70% improvement), 24 of 47 patients (51.1%) met the criterion, including 21 of 38 (55.3%) receiving monotherapy. Complete clearance was reported in 11 patients (23.4%). These proportions reflect outcomes reported in published cases and should not be interpreted as true response rates. Relapse was reported both during continued treatment and following withdrawal, highlighting uncertainty regarding the durability of response. Adverse effects were minimal, most commonly nausea, dizziness and vivid dreams and were reported in 15% of patients (7 of 47). Current reports suggest that naltrexone may represent a safe novel treatment option for patients with refractory HHD. However, this is based solely on very low level evidence, limited by publication bias, heterogeneous outcome definitions, incomplete reporting of seasonality, and concomitant treatments. Prospective controlled studies with standardised outcome measures, long-term follow-up across different seasons, and careful reporting of concomitant therapies are required to establish the efficacy, optimal dosing and long-term safety of naltrexone in HHD.
Authors
- Hannah Xuereb
- Michael John Boffa (ORCID: https://orcid.org/0000-0003-0489-8957)
Institutions
- University of South Wales (GB)
- Mater Dei Hospital (MT)
Publication Details
- Journal
- PubMed
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1093/ced/llag476
- Primary Topic
- Genetic and rare skin diseases.
- Type
- article
- Field-Weighted Citation Impact
- 0.00